J Lipid Atheroscler.  2019 May;8(1):48-49. 10.12997/jla.2019.8.1.48.

Circular RNA as a Possible Novel Biomarker for Kawasaki Disease

• Yoon KL

• KMID: 2447755
• DOI: http://doi.org/10.12997/jla.2019.8.1.48

Abstract

No abstract available.

MeSH Terms

Mucocutaneous Lymph Node Syndrome*
RNA*
RNA

Reference

1. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017; 135:e927–e999.

2. Hsiao KY, Sun HS, Tsai SJ. Circular RNA - New member of noncoding RNA with novel functions. Exp Biol Med (Maywood). 2017; 242:1136–1141.

3. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013; 495:384–388.

4. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010; 329:689–693.

5. Holdt LM, Stahringer A, Sass K, Pichler G, Kulak NA, Wilfert W, et al. Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. Nat Commun. 2016; 7:12429.

6. Boeckel JN, Jaé N, Heumüller AW, Chen W, Boon RA, Stellos K, et al. Identification and characterization of hypoxia-regulated endothelial circular RNA. Circ Res. 2015; 117:884–890.

7. Lin F, Zhao G, Chen Z, Wang X, Lv F, Zhang Y, et al. circRNA‑miRNA association for coronary heart disease. Mol Med Rep. 2019; 19:2527–2536.

8. Wu J, Zhou Q, Niu Y, Chen J, Zhu Y, Ye S, et al. Aberrant expression of serum circANRIL and hsa_circ_0123996 in children with Kawasaki disease. J Clin Lab Anal. 2019; e22874.

9. Kim YK. Analysis of circular RNAs in the coronary arteries of patients with Kawasaki disease. J Lipid Atheroscler. 2019; 8:50–57.